FOLFIRINOX方案与吉西他滨方案治疗局限性晚期胰腺癌疗效的对比研究  

Comparative study of FOLFIRINOX regimen and gemcitabine regimen in the treatment of localized advanced pancreatic cancer

作　　者：容谦[1] 周燕华[1] 洪瑞松 梁仲惠[2] RONG Qian;ZHOU Yanhua;HONG Ruisong;LIANG Zhonghui(Department of Radiotherapy,923 Hospital of Chinese People's Liberation Army,Guangxi Nanning 530021,China;Department of Gastroenterology,923 Hospital of Chinese People's Liberation Army,Guangxi Nanning 530021,China)

机构地区：[1]中国人民解放军第923医院放疗科,广西南宁530021 [2]中国人民解放军第923医院消化科,广西南宁530021

出　　处：《现代肿瘤医学》2021年第20期3605-3609,共5页Journal of Modern Oncology

基　　金：广西壮族自治区卫生厅科研课题(编号:Z2013538)。

摘　　要：目的:评估FOLFIRINOX方案与吉西他滨方案治疗局限性晚期胰腺癌(LAPC)患者的生存结果和副作用对比。方法:本研究共纳入129例进行FOLFIRINOX方案化疗和116例吉西他滨方案化疗的患者,比较两组患者总生存期(OS)、无进展生存期(PFS)以及治疗相关副作用和独立危险因素。结果:在129例接受了FOLFIRINOX系统化疗方案的LAPC患者中,中位OS为21.1个月,PFS为15.6个月;而吉西他滨方案组患者的中位OS为18.2个月,PFS为11.3个月。FOLFIRINOX组患者的总生存与吉西他滨组无统计学差异(P=0.167),但较吉西他滨组的无进展生存率高(P=0.005)。其中67.0%的患者同时完成了化疗和化疗后的放疗治疗,无一例因化疗而致死亡,45.7%的患者存在不同程度的化疗不良反应。肿瘤位置对预后有显著影响,肿瘤大小可影响LAPC患者总生存,但FOLFIRINOX化疗方案是LAPC患者无进展生存的独立危险因素。结论:FOLFIRINOX方案是LAPC患者治疗的有效手段,可提高无进展生存时间,且副作用与吉西他滨化疗方案相当。Objective:To evaluate the survival outcomes and side effects of the FOLFIRINOX and the gemcitabine in patients with localized advanced pancreatic cancer(LAPC)after chemotherapy.Methods:A total of 129 patients who underwent FOLFIRINOX chemotherapy and 116 with gemcitabine were included in the study.The overall survival(OS),progression-free survival(PFS),and treatment-related side effects and independent risk factors were compared between the two groups.Results:Of the 129 LAPC patients who received the FOLFIRINOX systemic chemotherapy,the median OS was 21.1 months and the PFS was 15.6 months.There was no significant difference in overall survival between the FOLFIRINOX group and the gemcitabine group(P=0.167),but a higher progression-free survival rate than the gemcitabine group(P=0.005).Among them,67.0%of patients completed radiotherapy after chemotherapy.There was no chemotherapy-induced death during treatment,but 45.7%of patients had varying degrees of chemotherapy side effects.Tumor location has a significant role in the prognosis of patients.In addition,tumor size can affect the overall survival of patients with LAPC,but FOLFIRINOX chemotherapy is an independent risk factor for progression-free survival in patients with LAPC.Conclusion:The FOLFIRINOX is an effective treatment for patients with LAPC,which can improve progression-free survival and has side effects comparable to traditional chemotherapy.

关 键 词：化疗 局部晚期胰腺癌 吉西他滨 FOLFIRINOX方案 

分 类 号：R735.9[医药卫生—肿瘤]